Oncology Reviews

, Volume 1, Issue 4, pp 195–204

Targeting survivin in leukemia

Review

Abstract

Survivin, a member of the inhibitors of apoptosis family of proteins, is one of the most frequently upregulated transcripts in solid tumors and hematopoietic malignancies. Survivin’s importance in tumorigenesis is attributed to the fact that it has two functions: to suppress apoptosis and to regulate cell division. The combination of these two functions gives a significant growth and survival advantage on neoplastic cells. This, together with its overexpression in cancer cells, its association with resistance to chemo-and other therapies, and the resulting poor prognosis observed in certain tumors makes survivin a promising target for therapy. In this review, we describe what is currently know about survivin regulation in normal and malignant cells, focusing in particular on the aberrant expression of the protein in leukemia and its possible clinical implications. Various strategies to target survivin will also be described.

Key words

Survivin Leukemia IAPs Expression Targeting 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schimmer AD (2004) Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64:7183–7190PubMedCrossRefGoogle Scholar
  2. 2.
    Conway EM, Pollefeyt S, Steiner-Mosonyi M et al (2002) Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology 123:619–631PubMedCrossRefGoogle Scholar
  3. 3.
    Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med 3:917–921PubMedCrossRefGoogle Scholar
  4. 4.
    Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54PubMedCrossRefGoogle Scholar
  5. 5.
    Konno R, Yamakawa H. Utsunomiya H et al (2000) Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod 6:529–534PubMedCrossRefGoogle Scholar
  6. 6.
    Endoh A, Asanuma K, Moriai R et al (2001) Expression of survivin mRNA in CD34-positive cells. Clin Chim Acta 306:149–151PubMedCrossRefGoogle Scholar
  7. 7.
    Fukuda S, Pelus LM (2001) Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 98:2091–2100PubMedCrossRefGoogle Scholar
  8. 8.
    Reed JC (2001) The Survivin saga goes in vivo. J Clin Invest 108:965–969PubMedCrossRefGoogle Scholar
  9. 9.
    Adida C, Crotty PL, McGrath J et al (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43–49PubMedGoogle Scholar
  10. 10.
    Li F (2003) Survivin study: what is the next wave? J Cell Physiol 197:8–29PubMedCrossRefGoogle Scholar
  11. 11.
    Li F, Altieri DC (1999) Transcriptional analysis of human survivin gene expression. Biochem J 344 Pt 2:305–311Google Scholar
  12. 12.
    Xu R, Zhang P, Huang J et al (2007) Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 356:286–292PubMedCrossRefGoogle Scholar
  13. 13.
    Li F, Ambrosini G, Chu EY et al (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584PubMedCrossRefGoogle Scholar
  14. 14.
    Mahboubi K, Li F, Plescia J et al (2001) Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab Invest 81:327–334PubMedGoogle Scholar
  15. 15.
    Kim PJ, Plescia J, Clevers H et al (2003) Survivin and molecular pathogenesis of colorectal cancer. Lancet 362:205–209PubMedCrossRefGoogle Scholar
  16. 16.
    Papapetropoulos A, Fulton D, Mahboubi K et al (2000) Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275:9102–9105PubMedCrossRefGoogle Scholar
  17. 17.
    Yang L, Cao Z, Li F et al (2004) Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther 11:1215–1223PubMedCrossRefGoogle Scholar
  18. 18.
    Carter BZ, Milella M, Altieri DC, Andreeff M (2001) Cytokine-regulated expression of survivin in myeloid leukemia. Blood 97:2784–2790PubMedCrossRefGoogle Scholar
  19. 19.
    Mitsiades CS, Mitsiades N, Poulaki V et al (2002) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21:5673–5683PubMedCrossRefGoogle Scholar
  20. 20.
    Pennati M, Folini M, Zaffaroni N (2007) Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28:1133–1139PubMedCrossRefGoogle Scholar
  21. 21.
    Kawakami H, Tomita M, Matsuda T et al (2005) Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer 115:967–974PubMedCrossRefGoogle Scholar
  22. 22.
    Carter BZ, Mak D, Schober WD et al (2006) Regulation of survivin expression through bcr-abl/MAPK cascade: targeting survivin overcomes Imatinib resistance and increases Imatinib sensitivity in Imatinib responsive CML cells. Blood 107:1555–1563PubMedCrossRefGoogle Scholar
  23. 23.
    Wang Z, Sampath J, Fukuda S, Pelus LM (2005) Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res 65:8224–8232PubMedCrossRefGoogle Scholar
  24. 24.
    Hoffman WH, Biade S, Zilfou JT et al (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277:3247–3257PubMedCrossRefGoogle Scholar
  25. 25.
    Mirza A, McGuirk M, Hockenberry TN et al (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613–2622PubMedCrossRefGoogle Scholar
  26. 26.
    Zhou M, Gu L, Li F et al (2002) DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 303:124–131PubMedCrossRefGoogle Scholar
  27. 27.
    Zhu N, Gu L, Findley HW et al (2006) KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem 281:14711–14718PubMedCrossRefGoogle Scholar
  28. 28.
    O’Connor DS, Grossman D, Plescia J et al (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 97:13103–13107PubMedCrossRefGoogle Scholar
  29. 29.
    Wheatley SP, Henzing AJ, Dodson H et al (2004) Aurora-B phosphorylation in vitro identifies a residue of survivin that is essential for its localization and binding to inner centromere protein (INCENP) in vivo. J Biol Chem 279:5655–5660PubMedCrossRefGoogle Scholar
  30. 30.
    Vong QP, Cao K, Li HY et al (2005) Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 310:1499–1504PubMedCrossRefGoogle Scholar
  31. 31.
    Zhao J, Tenev T, Martins LM et al (2000) The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 113 Pt 23:4363–4371.:4363–4371Google Scholar
  32. 32.
    Jolly C, Morimoto RI (2000) Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 92:1564–1572PubMedCrossRefGoogle Scholar
  33. 33.
    Fortugno P, Beltrami E, Plescia J et al (2003) Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A 100:13791–13796PubMedCrossRefGoogle Scholar
  34. 34.
    Arora V, Cheung HH, Plenchette S et al (2007) Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem 282:26202–26209PubMedCrossRefGoogle Scholar
  35. 35.
    Liston P, Fong WG, Kelly NL et al (2001) Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol 3:128–133PubMedCrossRefGoogle Scholar
  36. 36.
    Mahotka C, Liebmann J, Wenzel M et al (2002) Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 9:1334–1342PubMedCrossRefGoogle Scholar
  37. 37.
    Li F, Ling X (2006) Survivin study: an update of “what is the next wave”? J Cell Physiol 208:476–486PubMedCrossRefGoogle Scholar
  38. 38.
    Ling X, Cheng Q, Black JD, Li F (2007) Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax and survivin. J Biol Chem 282:27204–27214PubMedCrossRefGoogle Scholar
  39. 39.
    Zhu N, Gu L, Findley HW et al (2004) An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 23:7545–7551PubMedCrossRefGoogle Scholar
  40. 40.
    Ryan B, O’Donovan N, Browne B et al (2005) Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 92:120–124PubMedCrossRefGoogle Scholar
  41. 41.
    Dohi T, Beltrami E, Wall NR et al Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114:1117–1127Google Scholar
  42. 42.
    Altieri DC (2006) The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 18:609–615PubMedCrossRefGoogle Scholar
  43. 43.
    Tamm I, Wang Y, Sausville E et al (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:5315–5320PubMedGoogle Scholar
  44. 44.
    Du C, Fang M, Li Y et al (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33–42PubMedCrossRefGoogle Scholar
  45. 45.
    Song Z, Yao X, Wu M (2003) Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 278:23130–23140PubMedCrossRefGoogle Scholar
  46. 46.
    Marusawa H, Matsuzawa S, Welsh K et al (2003) HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 22:2729–2740PubMedCrossRefGoogle Scholar
  47. 47.
    Suzuki A, Ito T, Kawano H et al (2000) Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19:1346–1353PubMedCrossRefGoogle Scholar
  48. 48.
    Honda R, Korner R, Nigg EA (2003) Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 14:3325–3341PubMedCrossRefGoogle Scholar
  49. 49.
    Gassmann R, Carvalho A, Henzing AJ et al (2004) Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J Cell Biol 166:179–191PubMedCrossRefGoogle Scholar
  50. 50.
    Lee GH, Joo YE, Koh YS et al (2006) Expression of survivin in gastric cancer and its relationship with tumor angiogenesis. Eur J Gastroenterol Hepatol 18:957–963PubMedCrossRefGoogle Scholar
  51. 51.
    Marioni G, Bertolin A, Giacomelli L et al (2006) Expression of the apoptosis inhibitor protein Survivin in primary laryngeal carcinoma and cervical lymph node metastasis. Anticancer Res 26:3813–3817PubMedGoogle Scholar
  52. 52.
    Blanc-Brude OP, Mesri M, Wall NR et al (2003) Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 9:2683–2692PubMedGoogle Scholar
  53. 53.
    Sugahara K, Uemura A, Harasawa H et al (2004) Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. Int J Hematol 80:52–58PubMedCrossRefGoogle Scholar
  54. 54.
    Paydas S, Tanriverdi K, Yavuz S et al (2003) Survivin and aven: two distinct antiaptotic signals in acute leukemias. Ann Oncol 14:1045–1050PubMedCrossRefGoogle Scholar
  55. 55.
    Mori A, Wada H, Nishimura Y et al (2002) Expression of the antiapoptosis gene survivin in human leukemia. Int J Hematol 75:161–165PubMedCrossRefGoogle Scholar
  56. 56.
    Carter BZ, Kornblau SM, Tsao T et al (2003) Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 102:4179–4186PubMedCrossRefGoogle Scholar
  57. 57.
    Oto OA, Paydas S, Tanriverdi K et al (2007) Survivin and EPR-1 expression in acute leukemias: Prognostic significance and review of the literature. Leuk Res 31:1495–1501PubMedCrossRefGoogle Scholar
  58. 58.
    Adida C, Recher C, Raffoux E et al (2000) Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 111:196–203PubMedCrossRefGoogle Scholar
  59. 59.
    Troeger A, Siepermann M, Escherich G et al (2007) Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 92:1043–1050PubMedCrossRefGoogle Scholar
  60. 60.
    Che XF, Zheng CL, Owatari S et al (2006) Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines. Blood 107:4880–4887PubMedCrossRefGoogle Scholar
  61. 61.
    Nakayama K, Kamihira S (2002) Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hematooncology. Leuk Lymphoma 43:2249–2255PubMedCrossRefGoogle Scholar
  62. 62.
    Kamihira S, Yamada Y, Hirakata Y et al (2001) Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. Br J Haematol 114:63–69PubMedCrossRefGoogle Scholar
  63. 63.
    Lopes R, Castro I, Pontes P et al (2005) Expression profile of survivin in acute leukaemias: the importance of differential splicing. Leukemia 19:1284–1286PubMedCrossRefGoogle Scholar
  64. 64.
    Nakagawa Y, Hasegawa M, Kurata M et al (2005) Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL). Am J Hematol 78:173–180PubMedCrossRefGoogle Scholar
  65. 65.
    Badran A, Yoshida A, Wano Y et al (2003) Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome. Int J Oncol 22:59–64PubMedGoogle Scholar
  66. 66.
    Yamamoto K, Abe S, Nakagawa Y et al (2004) Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leuk Res 28:1203–1211PubMedCrossRefGoogle Scholar
  67. 67.
    Invernizzi R, Travaglino E, Lunghi M et al (2004) Survivin expression in acute leukemias and myelodysplastic syndromes. Leuk Lymphoma 45:2229–2237PubMedCrossRefGoogle Scholar
  68. 68.
    Gianelli U, Fracchiolla NS, Cortelezzi A et al (2007) Survivin expression in “low-risk” and “high-risk” myelodysplastic syndromes. Ann Hematol 86:185–189PubMedCrossRefGoogle Scholar
  69. 69.
    Sloand EM, Pfannes L, Chen G et al (2007) CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 109:2399–2405PubMedCrossRefGoogle Scholar
  70. 70.
    Badran A, Yoshida A, Wano Y et al (2003) Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res 23:589–592PubMedGoogle Scholar
  71. 71.
    Conte E, Stagno F, Guglielmo P et al (2005) Survivin expression in chronic myeloid leukemia. Cancer Lett 225:105–110PubMedCrossRefGoogle Scholar
  72. 72.
    Mori A, Wada H, Nishimura Y et al (2002) Expression of the antiapoptosis gene survivin in human leukemia. Int J Hematol 75:161–165PubMedGoogle Scholar
  73. 73.
    Hernandez-Boluda JC, Bellosillo B, Vela MC et al (2005) Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. Leuk Lymphoma 46:717–722PubMedCrossRefGoogle Scholar
  74. 74.
    Calabretta B, Perrotti D (2004) The biology of CML blast crisis. Blood 103:4010–4022PubMedCrossRefGoogle Scholar
  75. 75.
    Invernizzi R, Travaglino E, Benatti C et al (2006) Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia. Eur J Haematol 76:494–501PubMedCrossRefGoogle Scholar
  76. 76.
    Nakagawa Y, Yamaguchi S, Hasegawa M et al (2004) Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res 28:487–494PubMedCrossRefGoogle Scholar
  77. 77.
    Granziero L, Ghia P, Circosta P et al (2001) Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97:2777–2783PubMedCrossRefGoogle Scholar
  78. 78.
    Li F, Yang J, Ramnath N et al (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114:509–512PubMedCrossRefGoogle Scholar
  79. 79.
    Stauber RH, Mann W, Knauer SK (2007) Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 67:5999–6002PubMedCrossRefGoogle Scholar
  80. 80.
    Grossman D, McNiff JM, Li F, Altieri DC (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113:1076–1081PubMedCrossRefGoogle Scholar
  81. 81.
    Cao C, Mu Y, Hallahan DE, Lu B (2004) XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23:7047–7052PubMedCrossRefGoogle Scholar
  82. 82.
    Sharma H, Sen S, Lo ML et al (2005) Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther 4:720–727PubMedGoogle Scholar
  83. 83.
    Ansell SM, Arendt BK, Grote DM et al (2004) Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin’s lymphoma. Leukemia 18:616–623PubMedCrossRefGoogle Scholar
  84. 84.
    Sah NK, Munshi A, Hobbs M et al (2006) Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int J Radiat Oncol Biol Phys 66:852–859PubMedGoogle Scholar
  85. 85.
    Kanwar JR, Shen WP, Kanwar RK et al (2001) Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 93:1541–1552PubMedGoogle Scholar
  86. 86.
    Tu SP, Jiang XH, Lin MC et al (2003) Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63:7724–7732PubMedGoogle Scholar
  87. 87.
    Carter BZ, Wang RY, Schober WD et al (2003) Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle 2:488–493PubMedGoogle Scholar
  88. 88.
    Pennati M, Binda M, De Cesare M et al (2004) Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 25:1129–1136PubMedCrossRefGoogle Scholar
  89. 89.
    Pennati M, Binda M, Colella G et al (2003) Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 120:648–654PubMedCrossRefGoogle Scholar
  90. 90.
    Yang D, Welm A, Bishop JM (2004) Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci U S A 101:15100–15105PubMedCrossRefGoogle Scholar
  91. 91.
    Beltrami E, Plescia J, Wilkinson JC et al (2004) Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem 279:2077–2084PubMedCrossRefGoogle Scholar
  92. 92.
    Grossman D, Kim PJ, Schechner JS, Altieri DC (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 98:635–640PubMedCrossRefGoogle Scholar
  93. 93.
    Mesri M, Wall NR, Li J et al (2001) Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 108:981–990PubMedGoogle Scholar
  94. 94.
    Andersen MH, Thor SP (2002) Survivin-a universal tumor antigen. Histol Histopathol 17:669–675PubMedGoogle Scholar
  95. 95.
    Wobser M, Keikavoussi P, Kunzmann V et al (2006) Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 55:1294–1298PubMedCrossRefGoogle Scholar
  96. 96.
    Otto K, Andersen MH, Eggert A et al (2005) Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 23:884–889PubMedCrossRefGoogle Scholar
  97. 97.
    Xiang R, Mizutani N, Luo Y et al (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65:553–561PubMedGoogle Scholar
  98. 98.
    Nakahara T, Takeuchi M, Kinoyama I et al (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67:8014–8021PubMedCrossRefGoogle Scholar
  99. 99.
    Tolcher AW, Antonia S, Lewis LD et al (2006) A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors. ASCO Annual Meeting Proceedings 24[18S]Google Scholar
  100. 100.
    Chang CC, Heller JD, Kuo J, Huang RC (2004) Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A 101:13239–13244PubMedCrossRefGoogle Scholar
  101. 101.
    Mak DH, Schober WD, Chen W et al (2007) Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin. Leuk Lymphoma 48:774–785PubMedCrossRefGoogle Scholar
  102. 102.
    Huang RC, Chang CC, Mold D (2006) Survivin-dependent and-independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acid. Semin Oncol 33:479–485PubMedCrossRefGoogle Scholar
  103. 103.
    Plescia J, Salz W, Xia F et al (2005) Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7:457–468PubMedCrossRefGoogle Scholar
  104. 104.
    Gyurkocza B, Plescia J, Raskett CM et al (2006) Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst 98:1068–1077PubMedCrossRefGoogle Scholar
  105. 105.
    Wendt MD, Sun C, Kunzer A et al (2007) Discovery of a novel small molecule binding site of human survivin. Bioorg Med Chem Lett 17:3122–3129PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  1. 1.Department of Stem Cell Transplantation and Cellular TherapySection of Molecular Hematology and TherapyHoustonUSA
  2. 2.Department of LeukemiaThe University of Texas M.D. Anderson Cancer Center and Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular TherapyHoustonUSA

Personalised recommendations